What conclusions should be drawn from the association between liver diseases and cholelithiasis?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The authors reviewed current data, which could establish a pronounced association between the prevalence of cholelithiasis and liver diseases. A century-and-a-half discussion about the prevalence of the basic concepts of the pathogenesis of cholelithiasis led to the unification of metabolic and infectious theories. Currently, surgical tactics involving cholecystectomy in individuals with symptomatic or complicated cholelithiasis predominates in an approach to treating gallstones. A multidisciplinary view on the diagnosis, pathogenesis, treatment, and prevention of cholelithiasis and the recognition of a close relationship between the functional state and pathology of the liver and biliary tract justifies the feasibility of a thorough diagnosis of pathology of the liver and correction of its functional state in patients with cholelithiasis. Ursodeoxycholic acid is a good example of therapy that improves both the functional state of the liver and that of the biliary tract.

Full Text

Restricted Access

About the authors

Yu. L Tonkikh

Research Institute for Medical Problems of the North (Separate Subdivision) Federal Research Center «Krasnoyarsk Research Center Siberian Branch - Russian Academy of Sciences»

Email: gastro@impn.ru
Candidate of Medical Sciences Krasnoyarsk

A. V Vasyutin

Research Institute for Medical Problems of the North (Separate Subdivision) Federal Research Center «Krasnoyarsk Research Center Siberian Branch - Russian Academy of Sciences»

Email: gastro@impn.ru
Candidate of Medical Sciences Krasnoyarsk

V. V Tsukanov

Research Institute for Medical Problems of the North (Separate Subdivision) Federal Research Center «Krasnoyarsk Research Center Siberian Branch - Russian Academy of Sciences»

Email: gastro@impn.ru
Professor, MD Krasnoyarsk

References

  1. Kim Y.K., Kwon O.S., Her K.H. The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease: An observational Study. Medicine (Baltimore). 2019; 98 (27): e16018. doi: 10.1097/MD.0000000000016018
  2. Lee Y.C., Wu J.S., Yang Y.C. et al. Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease. Scand J Gastroenterol. 2014; 49 (8): 1001-6. doi: 10.3109/00365521.2014.920912
  3. Jaruvongvanich V., Sanguankeo A., Upala S. et al. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2016; 61 (8): 2389-96. DOI: 10.1007/ s10620-016-4125-2
  4. Kwak M.S., Kim D., Chung G.E. et al. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol. 2015; 21 (20): 6287-95. doi: 10.3748/wjg.v21.i20.6287
  5. Ruhl C.E., Everhart J.E. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population. Am J Gastroenterol. 2013; 108 (6): 952-8. doi: 10.1038/ajg.2013.70
  6. Benvegnu L., Noventa F., Chemello L. et al. Prevalence and incidence of cholecystolithiasis in cirrhosis and relation to the etiology of liver disease. Digestion. 1997; 58 (3): 293-8. doi: 10.1159/000201457
  7. Conte D., Fraquelli M., Fornari F. et al. Close relation between cirrhosis and gallstones: cross-sectional and longitudinal survey. Arch Intern Med. 1999; 159 (1): 49-52. doi: 10.1001/archinte.159.1.49
  8. Buchner A.M., Sonnenberg A. Factors influencing the prevalence of gallstones in liver disease: the beneficial and harmful influences of alcohol. Am J Gastroenterol. 2002; 97 (4): 905-9. doi: 10.1111/j.1572-0241.2002.05607.x
  9. Acalovschi M., Badea R., Pascu M. Incidence of gallstones in liver cirrhosis // Am. J. Gastroenterol. - 1991; 86 (9): 1179-81.
  10. Del Olmo J.A., Garcia F., Serra M.A. et al. Prevalence and incidence of gallstones in liver cirrhosis. Scand J Gastroenterol. 1997; 32 (10): 1061-5. doi: 10.3109/00365529709011225
  11. Elzouki A.N., Nilsson S., Nilsson P. et al. The prevalence of gallstones in chronic liver disease is related to degree of liver dysfunction. Hepatogastroenterology. 1999; 46 (29): 2946-50.
  12. Admirand W.H., Small D.M. The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest. 1968; 47 (5): 1043-52. DOI: 10.1172/ JCI105794
  13. Carey M.C. Pathogenesis of gallstones. Am J Surg. 1993; 165 (4): 410-9. doi: 10.1016/s0002-9610(05)80932-8
  14. Тонких Ю.Л., Цуканов В.В. Helicobacter Pylori и заболевания желчевыводящих путей: существует ли взаимосвязь? Врач. 2013; 10: 66-8
  15. Lammert F., Gurusamy K., Ko C.W. et al. Gallstones. Nat Rev Dis Primers. 2016; 2: 16024. doi: 10.1038/nrdp.2016.24
  16. Katsika D., Grjibovski A., Einarsson C. et al. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology. 2005; 41 (5): 1138-43. doi: 10.1002/hep.20654
  17. Nakeeb A., Comuzzie A.G., Martin L. Gallstones: genetics versus environment. Ann Surg. 2002; 235 (6): 842-9. doi: 10.1097/00000658-200206000-00012
  18. Lammert F., Miquel J.F. Gallstone disease: from genes to evidence-based therapy. J Hepatol. 2008; 48 (Suppl 1): S124-35. DOI: 10.1016/j. jhep.2008.01.012
  19. Buch S., Schafmayer C., Völzke H. et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet. 2007; 39 (8): 995-9. doi: 10.1038/ng2101
  20. Rebholz C., Krawczyk M., Lammert F. Genetics of gallstone disease. Eur J Clin Invest. 2018; 48 (7): e12935. doi: 10.1111/eci.12935
  21. Biddinger S.B., Haas J.T., Yu B.B. et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008; 14 (7): 778-82. doi: 10.1038/nm1785
  22. Lambert J.E., Ramos-Roman M.A., Browning J.D. et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014; 146 (3): 726-35. DOI: 10.1053/j. gastro.2013.11.049
  23. Tanaka N., Aoyama T., Kimura S. et al. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017; 179: 142-57. doi: 10.1016/j.pharmthera.2017.05.011
  24. Arab J.P., Karpen S.J., Dawson P.A. et al. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 2017; 65 (1): 350-62. doi: 10.1002/hep.28709
  25. Yu D.D., Andrali S.S., Li H. et al. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease. Bioorg Med Chem. 2016; 24 (18): 3986-93. doi: 10.1016/j.bmc.2016.06.039
  26. Drapkina O.M., Fomicheva E.I. Membrane bile acid receptor TGR5 - a new target in the study of metabolic, inflammatory and neoplastic diseases. Ration Pharmacother Cardiol. 2016; 12 (3): 344-50. doi: 10.20996/1819-6446-2016-12-3-344-350
  27. Liu C.M., Tung T.H., Tsai S.T. et al. Serum insulin, insulin resistance, betacell dysfunction, and gallstone disease among type 2 diabetics in Chinese population: a community-based study in Kinmen, Taiwan. World J Gastroenterol. 2005; 11 (45): 7159-64. doi: 10.3748/wjg.v11.i45.7159
  28. Цуканов В.В., Тонких Ю.Л., Васютин А.В. Липидный состав крови и желчи и риск развития желчнокаменной болезни у больных сахарным диабетом 1 и 2 типа. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (4): 36-40 https://doi.org/10.22416/1382-4376-2017-27-4-36-40
  29. Цуканов В.В., Селиверстова Е.В., Догадин С.А. Показатели липидного состава сыворотки крови и желчи при заболеваниях желчевыводящих путей у больных сахарным диабетом. Тер арх. 2005; 77 (2): 15-8.
  30. Цуканов В.В., Тонких Ю.Л., Бронникова Е.П. и др. Механизм нормоли-пидемии у северных народностей. Клин мед. 1999; 77 (2): 38-9.
  31. Цуканов В.В. Клинико-биохимические особенности заболеваний желчевыводящих путей у населения Азиатского Севера. Автореф. дис.. д-ра мед. наук. Томск, 1996; 40 c.
  32. Цуканов В.В., Ноздрачев К.Г., Тонких Ю.Л. и др. Метаболические факторы защиты коренного населения Севера при ИБС и холелитиазе. Бюллетень Сибирского отделения Российской академии медицинских наук. 2006; 26 (2): 100-4
  33. Scherber P.R., Züniga S.E., Glanemann M. et al. Gallstone disease -interdisciplinary treatment. Dtsch Med Wochenschr. 2020; 145 (5): 287-95. doi: 10.1055/a-0944-8655
  34. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016; 65 (1): 146-81. doi: 10.1016/j.jhep.2016.03.005
  35. Guarino M.P., Cocca S., Altomare A. et al. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol. 2013; 19 (31): 5029-34. doi: 10.3748/wjg.v19.i31.5029
  36. National Institutes of Health Consensus Development Conference Statement on Gallstones and Laparoscopic Cholecystectomy [No authors listed]. Am JSurg. 1993; 165 (4): 390-8. doi: 10.1016/s0002-9610(05)80929-8
  37. Beuers U., Boberg K.M., Chapman R.W. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51 (2): 237-67. doi: 10.1016/j.jhep.2009.04.009
  38. Portincasa P., Ciaula A.D., Bonfrate L. et al. Therapy of gallstone disease: What it was, what it is, what it will be. World J Gastrointest Pharmacol Ther. 2012; 3 (2): 7-20. doi: 10.4292/wjgpt.v3.i2.7

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies